M.E. Gleave - Concepedia

Author

M.E. Gleave

Vancouver General Hospital

Also Known As

M E Gleave, M Gleave, M. E. Gleave, M. Gleave, M.E. Gleave, Martin E Gleave

Publications

509

Citations

H-Index

Concepts

All Affiliations

Vancouver General Hospital University of British Columbia Sunnybrook Health Science Centre Hôpital Notre-Dame Vancouver Hospital and Health Sciences Centre

About

M.E. Gleave is an author at Vancouver General Hospital specializing in medicine, radiation oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	210
2	Health Sciences	1	1	23
3	Cell Biology	1	1	28
4	Endocrinology	1	1	81
5	Obstetrics	1	1	81

M.E. Gleave

Publications

466

Citations

H-Index

Page 1

	Year	Citations
Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study Laurent Lessard, L.R. Bégin, M.E. Gleave, British Journal of Cancer	2005	138
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Nicholas Bruchovsky, L.H. Klotz, Marianne D. Sadar, PubMed UrologyCanadian Prospective TrialGenitourinary CancerMedicineTumor Growth	2000	81
Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer M.E. Gleave, Hideaki Miyake, Toby Zellweger, Urology UrologyMedicineAntiapoptotic GeneHormonal ReceptorAndrogen Sensitivity	2001	78
Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinoma M. Elhilali, M.E. Gleave, Yves Fradet, British Journal of Urology	2000	58
Early experience with high‐intensity focused ultrasound for the treatment of benign prostatic hypertrophy Lorne D. Sullivan, Martin G. McLoughlin, Limor Goldenberg, British Journal of Urology	1997	45
Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter Dawei Yu, Christopher Charles Scott, Wenzhuo Jia, Cancer Gene Therapy MedicineLentiviral ConstructsTranslation Factor Eif4eProstate Cancer CellsAnti-cancer Agent	2005	28
Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). James B. Nelson, Karim Fizazi, Kathy D. Miller, Journal of Clinical Oncology Pain MedicineCancer ManagementPharmacotherapySpinal OncologyOsteoporosis	2011	23
Interferon Gamma-1b Compared With Placebo in Metastatic Renal-Cell Carcinoma M.E. Gleave, M. Elhilali, Yves Fradet, The Journal of Urology	1999	15

Page 1